Lung cancer risks, beliefs and healthcare access among the underprivileged

European Journal of Cancer Prevention

Volumn 24, Issue , 2015, Pages S82-S86

  Morère, Jean François ^a   Viguier, Jérôme ^b   Touboul, Chantal ^c   Pivot, Xavier ^d   Blay, Jean Yves ^e   Coscas, Yvan ^f   Lhomel, Christine ^g   Eisinger, François ^h,i  

^a HÔPITAL PAUL BROUSSE   (France)

^b Bretonneau Teaching Hospital   (France)

^c KANTAR HEALTH   (United States)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e CENTRE LÉON BÉRARD   (France)

^f Porte de St Cloud Clinic   (France)

^g Roche SAS   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ AIX MARSEILLE UNIV   (France)

Author keywords

Access to healthcare; Comorbidities; Lung cancer; Prevention; Risk factors; Smoking; Vulnerable population

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; COMORBIDITY ASSESSMENT; CURRENT SMOKER; FEMALE; HEALTH BELIEF; HEALTH CARE ACCESS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUANTITATIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SOCIAL STATUS; TOBACCO CONSUMPTION; VULNERABLE POPULATION; ADVERSE EFFECTS; ATTITUDE TO HEALTH; CULTURAL ANTHROPOLOGY; ECONOMICS; HEALTH CARE DELIVERY; HEALTH SURVEY; LUNG NEOPLASMS; MIDDLE AGED; SMOKING; SMOKING CESSATION; TRENDS;

ADULT; AGED; ATTITUDE TO HEALTH; CULTURE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTH SURVEYS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING; SMOKING CESSATION; VULNERABLE POPULATIONS;

EID: 84990873285     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000143     Document Type: Article

References (23)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al., National Lung Screening Trial Research Team (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409.
2. Birim O, Kappetein AP, Bogers AJ (2005). Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 28:759–762.
3. Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, et al. (2007). Survival of cancer patients in France: a population-based study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43:149–160.
4. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ (2013). Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (Suppl):e166S–e190S.
5. Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, et al. (2013). From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d’Oncologie de langue francaise (GOLF). Ann Oncol 24:586–597.
6. Del Giudice ME, Young SM, Vella ET, Ash M, Bansal P, Robinson A, et al. (2014). Systematic review of guidelines for the management of suspected lung cancer in primary care. Can Fam Physician 60:e395–e404.
7. Hill C (2012). Épidémiologie du tabagisme [Epidemiology of tobacco addiction]. Rev Prat 62:327–329.
8. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. (2014). ‘Sentinel’ circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 9:e111597.
9. Institut national du cancer (2014). Cancers in France in 2013 (Les cancers en France en 2013) Boulogne-Billancourt: INCa, Jan 2014. Available at: http://www.e-cancer.fr/publications/69-epidemiologie/758-les-cancers-enfrance-edition-2013.
10. INCa (2012). La situation du cancer en France en 2012 [The situation of cancer in France in 2012]. Available at: http://www.e-cancer.fr/publications/69-epidemiologie/629-la-situation-du-cancer-en-france-en-2012 [Accessed 10 March 2015].
11. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Moller H (2012). The effect of comorbidity on stage-specific survival in resected nonsmall cell lung cancer patients. Eur J Cancer 48:3386–3395.
12. Moro-Sibilot D, Aubert A, Diab S, Lantuejoul S, Fourneret P, Brambilla E, et al. (2005). Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 26:480–486.
13. Myrdal G, Gustafsson G, Lambe M, Horte LG, Stahle E (2001). Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg 20:694–699.
14. Peretti-Watel P, Constance J (2009a). “It's all we got left”. Why poor smokers are less sensitive to cigarette price increases. Int J Environ Res Public Health 6:608–621.
15. Peretti-Watel P, Constance J, Seror V, Beck F (2009b). Cigarettes and social differentiation in France: is tobacco use increasingly concentrated among the poor? Addiction 104:1718–1728.
16. Puri V, Crabtree TD, Bell JM, Kreisel D, Krupnick AS, Broderick S, et al. (2014). National cooperative group trials of ‘high-risk’ patients with lung cancer: are they truly ‘high-risk’? Ann Thorac Surg 97:1678–1683; discussion 1683–1685.
17. R Development Core Team (2012). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
18. Roussel C, Touboul C (2011). Large population survey: strengths and limits. Methodology of the EDIFICE survey. Eur J Cancer Prev 20 (Suppl 1): S5–S7.
19. Sass C, Moulin J-J, Guéguen R, Abric L, Dauphinot V, Dupré C, et al. (2006). Le score Epices: un score individuel de précarité. Construction du score et mesure des relations avec des données de santé, dans une population de 197 389 personnes [The EPICE score for individual deprivation. Building of the score and assessment with health data in a population of 197 389 individuals]. Bull Epidemiol Hebdo 14:93–96.
20. Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M (2013). The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5 (Suppl 1):3–29.
21. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P (2003). Impact of comorbidity on lung cancer survival. Int J Cancer 103:792–802.
22. Venables WN, Ripley BD (2002). Modern Applied Statistics with S, 4th ed. NY, USA: Springer.
23. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. (2013). Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax 68:551–564.